Our pipeline is focused on developing itolizumab as a potentially first-in-class treatment for multiple severe immuno-inflammatory disorders, including graft-versus-host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.


Phase 1

Phase 1b / 2

Phase 3


Biocon has received EUA in India

Positive FDA response to Pre-IND briefing package; if successful may suffice for BLA filing

IND submission pending for global DBPC study

  • Phase 2 Study Completed by Biocon in India
Completed by Biocon in India

EQ Study in Planning

Transplant Science

EQUATE Phase 1b/2 trial actively enrolling

Positive interim data announced Aug. 2020

  • Phase 1b/2
FDA Fast Track and
Orphan Drug Designation

Renal Disease

EQUALISE Phase 1b trial actively enrolling

  • Phase 1b
FDA Fast Track Designation


EQUIP Phase 1b trial actively enrolling

  • Phase 1b

Biocon completed a Phase 1 study in healthy volunteers in Australia.